Iterum Therapeutics to Host Conference Call
Iterum Therapeutics, a company dedicated to combating the rise of multi-drug resistant pathogens, is set to host a conference call to discuss an important milestone—the U.S. Food and Drug Administration (FDA) approval of ORLYNVAH™ (Oral Sulopenem). This groundbreaking approval signifies a major step in addressing the treatment of uncomplicated urinary tract infections (uUTIs).
Important Details About the Conference
The conference call will take place on the morning of Monday, October 28, 2024, at 8:30 a.m. Eastern Daylight Time. It will feature key leaders from Iterum Therapeutics, including Corey Fishman, the CEO, and Steve Aronin, Senior Vice President and Head of Clinical Development.
Context for Discussion
The focal point of the call will be ORLYNVAH™—a significant development in the treatment options available for women suffering from uUTIs, particularly those caused by common microorganisms like Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. This treatment stands out as it is the first oral penem approved by the FDA and marks Iterum's inaugural FDA product approval.
Why ORLYNVAH™ Matters
ORLYNVAH™ represents an important addition to the existing therapeutic landscape. Its approval addresses the urgent need for effective oral treatments for urinary tract infections, especially in cases where patients have limited or no other oral antibacterial options available. The availability of this medication can significantly enhance the well-being of affected individuals by offering a reliable treatment pathway.
Conference Call Access Information
Participants who wish to join the call can access it via the following dial-in numbers: for U.S. callers, dial +1 833-470-1428 and for international participants, call +1 404-975-4839. The access code for the conference is 936149. It is advisable to dial in a few minutes before the start time to ensure a prompt connection.
The Path Ahead for Iterum Therapeutics
Iterum Therapeutics is a biopharmaceutical company focused on advancing innovative anti-infective solutions. The company is actively working on treatments that are essential in fight against multi-drug resistant infections. Their flagship product, sulopenem, showcases high effectiveness against a variety of bacterial infections resistant to standard antibiotics.
Future Developments
In addition to ORLYNVAH™, Iterum is progressing with its pipeline of anti-infective candidates. The company has secured Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for multiple indications, reflecting the urgent need for new treatments in this field. The commitment to pushing boundaries in the development of effective therapies positions Iterum as a significant player in the biopharmaceutical landscape.
Frequently Asked Questions
What is the purpose of the conference call?
The conference call aims to discuss the recent FDA approval of ORLYNVAH™ for the treatment of uncomplicated urinary tract infections.
Who are the speakers at this event?
Speakers include Corey Fishman, CEO, and Steve Aronin, Senior Vice President and Head of Clinical Development at Iterum Therapeutics.
What is ORLYNVAH™?
ORLYNVAH™ (oral sulopenem) is the first oral penem approved by the FDA, designed for treating uncomplicated urinary tract infections in women.
How can I join the conference call?
To join, call +1 833-470-1428 for U.S. participants or +1 404-975-4839 for international participants, using the access code 936149.
What is Iterum Therapeutics focused on?
Iterum Therapeutics focuses on developing anti-infective medications targeting multi-drug resistant pathogens, aiming to improve patient outcomes in serious and life-threatening infections.
